Compositions employing a novel human kinase

• US 7,122,361 B2
• Filed: 10/10/2003
• Issued: 10/17/2006
• Est. Priority Date: 10/10/2002
• Status: Expired due to Fees

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Liu, Wei, Wu, Leeying
• Primary Examiner(s): Saidha, Tekchand
• Application Number:
  US10/684,190
• Publication Number:
  US 20040096889A1
• Time in Patent Office: 1,103 Days
• Field of Search: 435/194, 435/252.3, 435/320.1, 536/23.2
• US Class Current: 435/194
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: C12N 9/1205 Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
• CPC Class Codes: C12Q 1/485 involving kinase
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

This invention provides compositions, organisms and methodologies employing a novel human protein kinase, HPK3P23. The novel human kinase has sequence homology to the catalytic domains of several protein kinases. The gene encoding this novel protein kinase is localized in or near the 3p23 locus of the human chromosome 3. The sequence similarity between the novel human protein and the catalytic domain of protein kinases indicates that the novel human protein may function as a protein kinase.

Claims

1. An isolated polypeptide comprising a fragment of SEQ ID NO:

2, wherein said fragment comprising at least 500 consecutive amino acid residues of SEQ ID NO;

2.

2. An isolated polypeptide comprising SEQ ID NO:

2.